HiberGene
While the human toll of the disease has been terrible, IVD makers also report there have been some positive developments, as demand has spiked and familiarity with testing has grown.
HiberGene Molecular SARS-CoV-2 Test Gets CE Mark
With a €930,000 from Horizon 2020, the firm is conducting additional stories to evaluate other uses for the test, including using new specimen types and patient cohorts.
A handful of rapid 2019-nCoV assays are in the works which could help triage patients more effectively and avoid unnecessary quarantines.
The Dublin, Ireland-based company plans to launch its new instrument by the end of 2021 and will pursue CLIA waiver in the US.
HiberGene Gets CE Mark for Rapid Flu Combo MDx
The firm’s test for detecting flu and differentiating between subtypes A and B is being launched in Europe, Asia, and South America.
Oct 3, 2017
HiberGene Meningitis Test Gets CE Mark
Apr 12, 2017
Hibergene Closes €6.7M Series B Funding Round
Dec 15, 2016
HiberGene Launches CE-Marked C. Diff Test
Oct 18, 2016